ArticleResearch square2026
Global Burden of Cardiac Amyloidosis in Heart Failure: A Systematic Review and Meta-Analysis.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Cardiac amyloidosis (CA) is an infiltrative cardiomyopathy increasingly recognized as an important contributor to heart failure (HF), particularly with advances in noninvasive diagnostics. However, the global prevalence of CA remains poorly defined, with substantial variability across regions. We conducted a systematic review and meta-analysis of studies reporting the prevalence of CA among HF populations. The protocol was registered with PROSPERO and followed the PRISMA reporting guideline. Searches of PubMed Central, Cochrane, EMBASE and Web of Science identified eligible studies from inception through 2025. CA was diagnosed using technetium-labeled bone scintigraphy or biopsy. A random-effects proportional meta-analysis was conducted to estimate the pooled prevalence and assess geographic, subtype, sex-based, and study design-related differences. Twenty-eight studies encompassing 7,393 HF patients were included, of whom 627 were diagnosed with CA. The pooled prevalence of CA among HF patients was 10% (95% CI, 7%-13%), with substantial heterogeneity (prediction interval, 2-41%). Prevalence varied by region, ranging from 6% in North America to 15% in Asia, though subgroup differences were not statistically significant. Wild-type transthyretin amyloidosis (ATTRwt-CA) accounted for the majority of cases, representing 76% (95% CI, 57%-89%) of CA diagnoses and a pooled prevalence of 11% among screened populations. Approximately 24% of CA cases occurred in females. In conclusion, CA is present in one in ten patients with HF worldwide, with ATTRwt-CA being the predominant subtype. Uneven geographic distribution may suggest underdiagnosis, particularly in underrepresented regions and in females. Standardized, multinational studies are needed to define the global burden of CA better and guide equitable screening strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.